What Is Atenolol?
Atenolol is a selective 1 adrenergic blocker for moderate to mild hypertension caused by various reasons. It should be noted that atenolol can affect fetal hemodynamic status and cause fetal intrauterine developmental restriction in early pregnancy, so it is not recommended during pregnancy. This product is a cardiac selective -receptor blocker without membrane stabilization and endogenous sympathomimetic activity. Generally used for sinus tachycardia and premature beats. It can also be used for hypertension, angina pectoris and glaucoma. Oral absorption is about 50%, and small doses can cross the blood-brain barrier. Protein binding rate is 6-10%. The effect reached a peak 2 to 4 hours after taking it, and the effect lasted for a long time. The half-life is 6 to 7 hours, which is mainly excreted from the urine in its original form. Can be removed during hemodialysis.
- Drug Name
- Atenolol
- Alias
- Aminoacid
- Foreign name
- Atenolol
- Whether prescription drugs
- prescription
- Main indications
- Moderate and mild hypertension
- Dosage
- Adult oral: 50-100mg daily, divided into 1-2 times
- Adverse reactions
- Does not inhibit the bronchiectasis of isoproterenol,
- Atenolol is a selective 1 adrenergic blocker for moderate to mild hypertension caused by various reasons. It should be noted that atenolol can affect fetal hemodynamic status and cause fetal intrauterine developmental restriction in early pregnancy, so it is not recommended during pregnancy. This product is a cardiac selective -receptor blocker without membrane stabilization and endogenous sympathomimetic activity. Generally used for sinus tachycardia and premature beats. It can also be used for hypertension, angina pectoris and glaucoma. Oral absorption is about 50%, and small doses can cross the blood-brain barrier. Protein binding rate is 6-10%. The effect reached a peak 2 to 4 hours after taking it, and the effect lasted for a long time. The half-life is 6 to 7 hours, which is mainly excreted from the urine in its original form. Can be removed during hemodialysis.
Atenolol compound profile
Atenolol Basic Information
- Atenolol molecular formula
- Chinese name: atenolol
- Chinese aliases: Aminochloride; Tiannuomin; Atamole; Phenoxyamine; Sujianglingling; Atenolol-Zhulin-Ante; Aminochloride
- English name: atenolol
- English alias: Altol; 1-p-carbamoylmethylphenoxy-3-isopropylamino-2-propanol; atenol; 4- (2-hydroxy-3-[(1-methylethyl) amino] propoxy) benzeneacetamide; Ateni; Tenormin; Alinor; Target ' ; Atenolol (Tenormine)
- CAS number: 29122-68-7
- Molecular formula: C 14 H 22 N 2 O 3
- Molecular weight: 266.33600
- Exact mass: 266.16300
- PSA: 84.58000
- LogP: 1.54330
Atenolol physical and chemical properties
- Appearance and properties: white to off-white crystalline powder
- Density: 1.125 g / cm 3
- Melting point: 154 ° C
- Boiling point: 508ºC at 760 mmHg
- Flash point: 261.1ºC
- Storage conditions: Keep in a cool, dry, dark container.
- Vapor pressure: 3.82E-11mmHg at 25 ° C
Atenolol safety information
- Customs Code: 2924299090
- WGK Germany: 2
- Danger category code: R22; R36 / 37/38; R20 / 21/22
- Safety instructions: S22; S24 / 25; S36; S26
- RTECS number: AC3600000
- Dangerous goods mark: Xn [2]
Atenolol Pharmacopoeia Standard
Atenolol source (name), content (potency)
- This product is 4- [3- (2-hydroxy-3-isopropylamino) propoxy] phenylacetamide. Calculated on dry basis, C 14 H 22 N 2 O 3 should be 98.0% 102.0%.
Atenolol traits
- This product is white powder; no odor or slight odor.
- This product is soluble in ethanol, slightly soluble in chloroform or water, and almost insoluble in ether.
- Melting point
- The melting point of this product (Appendix VIC of Part Two of the 2010 Pharmacopoeia) is 151 to 155 ° C.
Atenolol identification
- (1) Take this product, add absolute ethanol to make a solution containing 10 g per 1 ml, and measure according to ultraviolet-visible spectrophotometry (Appendix IVA of Pharmacopoeia Part II of 2010 Edition). absorb.
- (2) The infrared absorption spectrum of this product should be the same as that of the control ("Infrared Spectra of Drugs" 214).
Atenolol check
- Clarity of the solution
- Take 50mg of this product, add 10ml of water and 5ml of dilute hydrochloric acid to dissolve, the solution should be clear.
- relative substance
- Take about 10mg of this product, weigh it accurately, place it in a 100ml measuring bottle, add the appropriate amount of mobile phase, dissolve and dilute to the mark with ultrasound, shake well, and use it as the solution for the test; The mobile phase was diluted to the mark, shaken, and used as a control solution. According to the chromatographic conditions under the content determination item, take 20 l of the control solution, inject it into the liquid chromatograph, and adjust the detection sensitivity so that the peak height of the main component chromatographic peak is about 20% of the full range; accurately measure the test solution and the control solution Each 20 l was injected into a liquid chromatograph, and the chromatogram was recorded to 3 times the peak retention time of the main component. If there are impurity peaks in the chromatogram of the test solution, the sum of the area of each impurity peak must not be greater than the main peak area (1.0%) of the control solution.
- Loss on drying
- Take this product and dry it at 105 to constant weight, and the weight loss shall not exceed 1.0% (Appendix L of Part Two of the Pharmacopoeia of 2010 Edition).
- Residue on ignition
- Must not exceed 0.1% (Appendix N of Part Two of the 2010 Pharmacopoeia).
Determination of atenolol
- It was determined by high performance liquid chromatography (Appendix VD of Part Two of the Pharmacopoeia, 2010 Edition).
- 1 Chromatographic conditions and system suitability tests
- Octadecylsilane-bonded silica gel as filler; phosphate buffer solution (take 6.8 g of potassium dihydrogen phosphate, 1.3 g of sodium octane sulfonate, dissolve in water and dilute to 1000 ml, adjust the pH to 3.0 with phosphoric acid) -Methanol (70:30) was used as the mobile phase; the detection wavelength was 226 nm. The number of theoretical plates is calculated to be not less than 2000 by atenolol peak. The resolution of atenolol peak from adjacent impurity peaks should meet the requirements.
- 2 Assay
- Take about 25mg of this product, accurately weigh it, place it in a 100ml measuring bottle, add the appropriate amount of mobile phase, dissolve and dilute to the mark with ultrasound, shake well, take 2ml of precise amount, place it in a 10ml measuring bottle, and dilute to the mark with mobile phase. Shake well, accurately measure 20 l, inject it into the liquid chromatograph, and record the chromatogram; take another atenolol reference substance and measure it in the same way. Calculate the peak area according to the external standard method, and get [3] .
Atenolol Categories
- Beta adrenaline blockers.
Atenolol storage
- Keep sealed.
Atenolol
- Atenolol tablets
Atenolol Drug Analysis
- Method name: Atenolol API-atenolol-high performance liquid chromatography
- Scope of application: This method uses high performance liquid chromatography to determine the content of atenolol in the atenolol drug substance.
- This method is applicable to atenolol APIs.
- Principle of the method: The test sample is dissolved in the mobile phase and quantitatively diluted. After the internal standard is added, the sample is diluted with the mobile phase, and then enters a high-performance liquid chromatography for chromatographic separation. The ultraviolet absorption detector is used to detect atenolol at a wavelength of 275 nm Peak area and calculate its content.
- Reagent: 1. Phosphate buffer
- Methanol
- Sodium octane sulfonate
- Finacetin
- Equipment: 1. Instrument
- 1 HPLC
- 2 Column
- Octadecylsilane-bonded silica gel is used as a filler, and the theoretical number of plates based on atenolol peak should not be less than 2000.
- 3 UV absorption detector
- Chromatographic conditions
- 1 Mobile phase: Phosphate buffered methanol = 73, containing 1.30g of sodium octane sulfonate per 1000mL
- 2 Detection wavelength: 275nm
- 3 Column temperature: room temperature
- Sample preparation: 1. Phosphate buffer
- Take 6.8 g of potassium dihydrogen phosphate, dissolve with water and dilute to 1000 mL, and adjust the pH to 3.0 with phosphoric acid.
- Preparation of internal standard solution
- Accurately weigh the appropriate amount of phenacetin and add the mobile phase to make a solution containing 80 & microg per 1 mL, which is the internal standard solution.
- Preparation of reference solution
- Accurately weigh the appropriate amount of atenolol reference, add the appropriate amount of mobile phase, sonicate for 20 minutes to dissolve, quantitatively dilute with mobile phase to a solution containing 0.32mg per 1mL, and accurately measure 5mL each of this solution and the internal standard solution. Place in a 25mL volumetric flask, add mobile phase to dilute to the mark, and shake well to obtain the reference solution.
- Preparation of test solution
- Accurately weigh the appropriate amount of test product, add the appropriate amount of mobile phase, sonicate for 20 minutes to dissolve, and quantitatively dilute with mobile phase to a solution containing 0.32mg per 1mL. Precisely measure 5mL each of this solution and the internal standard solution, and set the amount to 25mL In the bottle, add the mobile phase and dilute to the mark. Shake well to obtain the test solution.
- Note: "Precision weighing" means that the weighed weight should be accurate to one thousandth of the weighed weight. "Precision measurement" means that the accuracy of measuring the volume should meet the accuracy requirements of the volume pipette in national standards.
- Operation steps: Precisely draw 20 mL of each of the reference solution and the test solution, inject them into a high-performance liquid chromatograph, and measure the peak of atenolol (C 14 H 22 N 2 O 3 ) with a UV absorption detector at a wavelength of 275 nm. Area, and calculate its content [4] .
Atenolol Drug Description
Atenolol classification
- Circulatory System Drugs> Antiarrhythmic Drugs> -Adrenergic Blockers
Atenolol dosage form
- 1. Eye drops: 1% to 4%;
- 2. Tablet: 25mg, 50mg, 100mg.
Atenolol pharmacological action
- Atenolol has a selective blocking effect on 1 receptors and has a low affinity for 2 receptors on bronchial smooth muscle. Smaller doses can significantly reduce animal heart rate, cardiac contractility, and cardiac output, and lower blood pressure. Atenolol has no intrinsic sympathomimetic activity and membrane stabilization, and can reduce plasma renin and renin activity and AG levels. There is no myocardial inhibitory effect. Diffusion into the ciliary epithelium through the ciliary muscle reduces the production of aqueous humor and reduces intraocular pressure.
Atenolol pharmacokinetics
- The oral absorption rate is 50%, the bioavailability is low, about 40%, the blood drug concentration reaches the peak 2 to 3 hours after taking the drug, the drug-plasma protein binding rate is 5% to 10%, and the half-life is 6 to 9 hours. . In renal insufficiency, the half-life is significantly prolonged. Without metabolism by the liver, 50% of the oral dose is excreted from the feces in the original form, and 40% to 50% is excreted from the kidneys; it can be cleared by hemodialysis [5] .
Atenolol indication
- High blood pressure Atenolol is a first-line antihypertensive drug, which can be used alone or in combination with other drugs (such as diuretics and vasodilators).
- Angina pectoris
- 3. Myocardial infarction.
- 4. Arrhythmia. Used to correct supraventricular arrhythmias, ventricular arrhythmias, digital arrhythmia and catecholamine-induced tachyarrhythmias.
- 5. Hyperthyroidism.
- 6. Pheochromocytoma.
- 7. Atenolol eye drops are used in open-angle glaucoma and other angle-closing glaucoma, neovascular glaucoma, and ciliary ring-blocking glaucoma (malignant glaucoma). [5] .
Atenolol contraindications
- 1. Bronchial asthma.
- 2. Cardiogenic shock.
- 3. II to III degree AV block.
- 4. Severe heart failure.
- 5. Sinus bradycardia.
- 6. Pregnant women are disabled [5] .
Atenolol precautions
- 1. (1) history of allergies; (2) congestive heart failure; (3) diabetes; (4) emphysema or non-allergic bronchitis; (5) liver insufficiency; (6) hypothyroidism; (7) ) Raynaud's syndrome or other peripheral vascular disease; (8) renal failure; (9) pregnant and lactating women.
- 2. Avoid taking medication while eating.
- 3. The clinical effect of atenolol is not completely parallel to the blood concentration. The dose adjustment should be based on the clinical effect. However, it takes 1 to 2 weeks to achieve the best antihypertensive effect, so it should be observed for a period of time to determine the treatment effect.
- 4. Patients with symptoms of heart failure should be given digitalis or diuretics before using atenolol. If the symptoms persist, atenolol should be gradually reduced to discontinuation.
- 5. The dose should be reduced when the drug is stopped. Sudden withdrawal of medication in patients with angina pectoris can lead to worsening angina pectoris and even myocardial infarction; hypertensive patients can cause hypertension to rebound. Therefore, when the drug is stopped, the dose should be gradually reduced, and physical activity should be restricted as much as possible.
- 6. Intravenous administration can quickly control heart rate and myocardial contractility. Studies have shown that intravenous administration is better than oral administration within a few hours of the onset of myocardial infarction symptoms. After myocardial infarction, intravenous administration and then oral administration are better than one method alone.
- 7. Treatment of overdose: bradycardia can be given atropine or isoproterenol, an artificial pacemaker can be installed if necessary, ventricular premature beats can be given lidocaine or phenytoin; heart failure can be given oxygen, Digitalis or diuretics; infusion and booster drugs when hypotension; diazepam or phenytoin sodium when convulsions; isoproterenol should be given when bronchospasm. Atenolol can be cleared by hemodialysis [5] .
Atenolol adverse reactions
- Cold limbs, fatigue, gastrointestinal upset, and bradycardia may occur. Occasionally, headaches, mood changes, and heart failure worsened. Rare sleep disorders, depression, hair loss, thrombocytopenia, purpura, psoriasis-like skin reactions, worsening psoriasis, blurred vision, fantasy or orthostatic hypotension. The most common adverse reactions in patients with myocardial infarction are hypotension and bradycardia. Dizziness, dizziness, insomnia, dreaminess, nausea, diarrhea and abdominal discomfort, difficulty breathing, increased serum very low density lipoprotein and triacylglycerol levels, rash, joint pain, chest pain, etc., can induce heart failure or make the original heart Exacerbation and bronchospasm are exacerbated, but they are lighter than non-selective beta-blockers and have a lower incidence [5] .
Atenolol dosage
- 1.1% to 4% solution, 1 or 2 drops each time, 3 to 4 times a day.
- 2. Oral 50 to 100 mg each time, 2 times a day, the maximum amount of 600 mg per day.
Atenolol drug interactions
- 1. It can aggravate the first dose response of 1 blockers. In addition to prazosin, other 1 blockers are rare, but they should still be used with atenolol.
- 2. Combined with amiodarone, obvious bradycardia and sinus arrest can occur.
- 3. Combining with propiomine can cause a significant decrease in cardiac output, such as combined use should closely monitor cardiac function, especially for patients with potential heart disease.
- 4. Combined with phenelzine can cause a decrease in heart rate. If combined, it should be carefully monitored.
- 5. Quinidine can enhance beta receptor blockade and cause orthostatic hypotension. If they must be used together, the dosage of the two drugs should be small and should be carefully monitored.
- 6. Combined with lisepine, the two functions work synergistically, -blocking effect is enhanced, bradycardia and hypotension can occur.
- 7. Combination with dihydropyridine calcium channel blockers is effective in treating angina pectoris or hypertension, but it can also cause severe hypotension or decreased heart reserve. If combined, cardiac function should be carefully monitored, especially in patients with impaired left ventricular function, arrhythmias, or aortic stenosis.
- 8. Diltiazem can enhance the pharmacological effects of beta-blockers and is beneficial to patients with normal cardiac function. However, there have been reports of hypotension, left ventricular failure, and atrioventricular block after combined use. If combined, the patient's cardiac function should be closely monitored, especially when the elderly, left ventricular failure, aortic stenosis, and the use of both drugs are large.
- 9. Verapamil and atenolol both have direct negative muscle strength and negative conduction, and combined use may cause hypotension, bradycardia, congestive heart failure, and conduction disorders. The risk increases with left ventricular dysfunction, aortic stenosis, or both doses. Cardiac function should be closely monitored when the two drugs are combined.
- 10. Co-administration with mibediril can cause hypotension, bradycardia, or decreased heart reserve. Mbetidil should be discontinued for 7 to 14 days before starting beta blocker therapy. If combined, cardiac function should be monitored, especially in elderly patients with decreased left ventricular function, decreased cardiac conduction function, or aortic stenosis.
- 11. Combined with oloflex, it can cause hypotension or hypertension with bradycardia. If combined, patients' blood pressure and heart rate should be closely monitored.
- 12. Atenolol can cause severe hypotension during fentanyl anesthesia.
- 13. Combination with digoxin can lead to prolonged atrioventricular conduction time, and can increase the blood concentration of digoxin. When combined, the electrocardiogram and the blood plasma concentration of digoxin should be carefully monitored and the dose adjusted accordingly.
- 14. Although there is no report on the interaction between benzprodil, flunarizine, lidofloxazine, golopamide, perhexiline and atenolol, all of these drugs can reduce myocardial contraction and reduce Slow atrioventricular node conduction can cause lower blood pressure, bradycardia, or decreased heart reserve, so if it must be used together, cardiac function should be monitored, especially in patients with decreased left ventricular function, decreased cardiac conduction function, or aortic stenosis.
- 15. Although there is no report on the interaction between chlorpromazine, cloprothion or triflupromazine and atenolol, the combination of phenothiazines and beta-blockers can strengthen each other, causing Hypotension and phenothiazine poisoning. The combined effect of the two drugs should be monitored for potentiation and the dose should be reduced if necessary.
- 16. When atenolol is treated with clonidine, sudden withdrawal of clonidine may exacerbate hypertension. Therefore, when withdrawing cola, we should first remove atenolol, closely monitor blood pressure, and then gradually reduce clonidine after a few days. Caution should be taken when using Mosulidine in combination with sudden withdrawal of Mosulidine.
- 17. At the same time of intravenous administration with doracen, atenolol can reduce the elimination of active metabolites of doracen and increase the risk of adverse reactions.
- 18. Beta-blockers can aggravate or prolong bronchoconstriction, so patients taking atenolol should avoid inhaling methacholine.
- 19. It can enhance the efficacy of non-depolarizing muscle relaxants, such as dartyl chloride, goradium ammonium, and prolong the action time.
- 20. Combined with quasi-sympathetic amines such as epinephrine, phenylephrine, epinephrine, and epinephrine, it can cause a significant increase in blood pressure, slow heart rate, and atrioventricular block. Therefore, cardiac function must be closely observed.
- 21. When combined with methyldopa, very few patients can have abnormal reactions to endogenous or exogenous catecholamines, such as hypertension, tachycardia, or arrhythmia.
- 22. Combination with non-steroidal anti-inflammatory drugs can cause blood pressure to rise. If combined, the patient's blood pressure should be monitored and the dose adjusted accordingly.
- 23. Ampicillin or ampicillin / sulbactam can reduce the plasma concentration of atenolol. If combined, monitor blood pressure and adjust atenolol dosage if necessary.
- 24. Antacids can reduce the bioavailability and efficacy of atenolol. Therefore, atenolol should be given 1 hour before or 6 hours after taking antacids.
- 25. Abutamine has -receptor agonistic effect. If atenolol is used in combination, the effect is weakened. Therefore, atenolol should be discontinued for at least 48 hours before using abutamin.
- 26. Beta-blockers can antagonize the effects of ritodrine, so the combination of atenolol and ritodrine should be avoided.
- 27. Atenolol can reduce the efficacy of isoprenaline or xanthine.
- 28. Cardiac selective beta-blockers are less likely to cause impaired glucose tolerance in patients with type 2 diabetes, but diabetic patients should still pay attention when using atenolol and hypoglycemic agents.
- 29. Atenolol has no obvious interaction with benazepril and fluvoxamine.
- 30. Food can reduce the bioavailability of atenolol [5] .
Atenolol expert reviews
- Beta adrenergic blockers are referred to as beta blockers. It is a kind of cardiovascular drug widely used in clinical practice. It has significant effects on a variety of cardiovascular diseases such as hypertension, myocardial ischemia, myocardial infarction, cardiomyopathy and arrhythmia. Recent clinical studies have shown that beta blockers Can reduce the overall mortality and sudden death rate of patients with CHF, and has become an indispensable treatment in addition to the standard triple therapy of heart failure (ACE I diuretic digoxin). After atenolol is applied topically, it takes effect within 1 hour, reaches its peak in 2 to 3 hours, lasts for 7 hours, and has the greatest effect in 2 to 5 hours when taken orally [5] .
Atenolol tablets
- [Drug name]
- Common name: Atenolol tablets
- Previous name:
- Product name:
- English name: Atenolol Tablets
- Phonetic script (Hanyu Pinyin): Atiluo'erPin
- The chemical name of this product is: 4- [3-[(1-methylethyl) amino-2-hydroxy] propoxy] phenylacetamide.
- Structural formula:
- Molecular formula: C14H22N2O3
- Molecular weight: 266.34
- [Character]
- This product is a white tablet or a sugar-coated tablet, which appears white after removing the sugar coating.
- [Pharmacology and Toxicology]
- It is a selective b 1 adrenergic receptor blocker without membrane stabilization and endogenous sympathomimetic activity. But does not inhibit the bronchiectasis of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce mortality from 0 to 7 days in acute myocardial infarction. The treatment dose did not significantly inhibit myocardial contractility.
- Pharmacokinetics
- Oral absorption is fast, but incomplete. Oral absorption is 50%, reaching peak concentration in 2 to 4 hours. After oral administration, the effect lasts for a long time, up to 24 hours. It is widely distributed in various tissues and can pass through the blood-cerebrospinal fluid barrier in small amounts. . The distribution volume of healthy people is about 50 ~ 75L. The half-life in blood is 6 to 7 hours, which is mainly excreted from the urine in the original form. The half-life is prolonged when renal function is impaired, and can be accumulated in the body. It can be cleared during hemodialysis. This product has low lipid solubility, low penetration into brain tissues, and extremely low plasma protein binding rate (6% to 16%).
- [Indications]
- Mainly used for the treatment of hypertension, angina pectoris, myocardial infarction, but also for arrhythmia, hyperthyroidism, and pheochromocytoma.
- Dosage
- oral. The usual dosage for adults: 6.25 to 12.5 mg each time, twice a day, and gradually increased to 50 to 200 mg as needed and tolerated. When renal function is impaired, the creatinine clearance rate is less than 15ml / (min · 1.73m), 25mg per day; 15 ~ 35ml / (min · 1.73m), the maximum is 50mg per day.
- Adverse reactions
- In patients with myocardial infarction, the most common adverse reactions are hypotension and bradycardia;
- Other reactions may include dizziness, cold limbs, fatigue, fatigue, gastrointestinal upset, depression, hair loss, thrombocytopenia, psoriasis-like skin reactions, exacerbation of psoriasis, rash, and dry eyes.
- Rarely causes cardiac block in sensitive patients.
- [Taboo]
- (1) - degree cardiac block.
- (2) Those with cardiogenic shock.
- (3) Sick sinus syndrome and severe sinus bradycardia.
- Precautions
- The clinical effect of this product may not be completely parallel to the blood concentration. The dose adjustment shall be based on the clinical effect. The dose should be reduced when renal function is impaired. When patients with heart failure symptoms use this product, digitalis or diuretics are used in combination, such as Symptoms of heart failure still exist, should be gradually reduced; the withdrawal process of this product is at least 3 days, often up to 2 weeks, if there are withdrawal symptoms, such as angina pectoris, then temporarily re-administer, and gradually stop after stabilization Coexisting with the diet does not affect its bioavailability; this product can change tachycardia caused by lowering blood sugar; used with caution in hypertensive patients with chronic obstructive pulmonary disease; this drug can cause peripheral arterial blood circulation disorders, Patients may not respond to adrenaline at the usual doses used to treat allergic reactions.
- [Medication for pregnant and lactating women]
- This product can pass through the placental barrier and appear in umbilical cord blood. The lack of research on the use of this drug in the first 3 months does not rule out the possibility of fetal damage. Pregnant women taking this medicine for a long time are related to intrauterine growth retardation. This medicine has a significant agglomeration effect in breast milk, and should be used with caution when lactating women.
- [Medication for elderly patients]
- The required dose can be reduced, especially in patients with impaired renal function.
- [Child medication]
- It should be used in children from 0.25 to 0.5 mg / kg, twice daily. Pay attention to monitoring heart rate and blood pressure.
- medicine interactions
- Combined with other antihypertensive drugs and diuretics, it can enhance its antihypertensive effect. Class I antiarrhythmic drugs, verapamil, and anesthetics should be especially cautious. B -receptor blockers will aggravate the rebound of hypertension caused by discontinuation of clonidine. If two drugs are used in combination, this drug should be discontinued a few days before clonidine is discontinued. If clonidine is replaced with this drug, B -blockers should not be started until several days after taking clonidine.
- [Drug overdose]
- For excessive bradycardia, 1 to 2 mg of atropine can be injected intravenously. If necessary, a large amount of glucagon 10 mg can be injected intravenously. The response can be repeated or subsequent intravenous drip of glucagon 1 to 10 mg / hour, if not expected. For effect, or without glucagon supply, b -receptor stimulants can be used [6] .
- specification
- (1) 12.5mg (2) 25mg (3) 50mg (4) 100mg
- Storage
- Keep sealed.
Comparison of Atenolol Pharmacopoeia Standards
- Product Name: Atenolol
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| ||
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
| ||||
|
|
|
| ||
|
|
| |||
|
|
|
|
|
|